Stratipath makes AI-based precision diagnostics accessible in everyday clinical practice
How can AI be used to assess the risk of recurrence in cancer patients? This is a question that Johan Hartman and Mattias Rantalainen have been collaborating on for a long time, and one for which a solution now exists: the product Stratipath Breast.
Fredrik Wetterhall, CEO of Stratipath.
“Using AI, we can perform prognostic analyses based on pathological images. Such information is extremely valuable to oncologists when making treatment decisions, especially for patients who are difficult to assess and often end up in an intermediate-risk group. These are patients with a confirmed cancer,” says Fredrik Wetterhall, CEO of Stratipath.
Our newsletter focuses primarily on life science and highlights key players, topics and development within the innovation ecosystem in the Stockholm-Uppsala region.
